Baxter International (NYSE:BAX) Posts Earnings Results

Baxter International (NYSE:BAX) released its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09, RTT News reports. Baxter International had a return on equity of 22.41% and a net margin of 9.12%. The firm had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.87 billion. During the same quarter in the previous year, the company posted $0.80 EPS. The business’s revenue was up .4% on a year-over-year basis. Baxter International updated its Q1 2020
Pre-Market guidance to 0.72-0.74 EPS and its Q1 guidance to $0.72-0.74 EPS.

Shares of Baxter International stock opened at $78.17 on Friday. Baxter International has a one year low of $69.10 and a one year high of $95.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.32 and a quick ratio of 2.10. The stock’s 50-day moving average is $87.69 and its 200 day moving average is $85.51. The firm has a market cap of $42.91 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 2.02 and a beta of 1.00.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Friday, February 28th will be given a dividend of $0.22 per share. The ex-dividend date is Thursday, February 27th. This represents a $0.88 annualized dividend and a dividend yield of 1.13%. Baxter International’s payout ratio is 26.59%.

A number of equities research analysts have commented on BAX shares. Morgan Stanley upgraded Baxter International from an “equal weight” rating to an “overweight” rating in a research report on Thursday, January 2nd. Stifel Nicolaus upgraded Baxter International from a “hold” rating to a “buy” rating and upped their price target for the company from $87.00 to $95.00 in a research report on Thursday. Goldman Sachs Group started coverage on Baxter International in a research report on Wednesday, February 12th. They issued a “buy” rating and a $104.00 price target on the stock. Credit Suisse Group reduced their price target on Baxter International from $98.00 to $96.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, SVB Leerink restated an “outperform” rating on shares of Baxter International in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $92.16.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: What is the CAC 40 Index

Earnings History for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with's FREE daily email newsletter.